Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Idiopathic Thrombocytopenic Purpura: early-phase trial registry
A small indexed set (2 trials) with no open enrollment listed right now.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · none currently recruiting · #7,188 of 28,707 conditions by registered trial count
Idiopathic Thrombocytopenic Purpura: 2 US clinical trials tracked, none currently recruiting.
Idiopathic Thrombocytopenic Purpura is the subject of 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Neufeld, Ellis J, MD, PhD, running 1 of these trials.
Enrollment posture brief
Registry condition idiopathic-thrombocytopenic-purpura
OPEN 0 | RECR 0% | LATE 0 | EARLY 1 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Idiopathic Thrombocytopenic Purpura has no open enrollment in this registry pull (2 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Idiopathic Thrombocytopenic Purpura on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Idiopathic Thrombocytopenic Purpura is recruiting below its size-band peers.
0 of 2 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
2 total, page 1 of 1
An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias
Alpine Immune Sciences
NCT05757570
Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura
Neufeld, Ellis J, MD, PhD
NCT01713855
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Idiopathic Thrombocytopenic Purpura records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Idiopathic Thrombocytopenic Purpura trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Idiopathic Thrombocytopenic Purpura page
2 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Idiopathic Thrombocytopenic Purpura trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Neufeld, Ellis J, MD, PhD sponsors the most Idiopathic Thrombocytopenic Purpura trials on record, review their full trial history before evaluating a specific study. See Neufeld, Ellis J, MD, PhD's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Idiopathic Thrombocytopenic Purpura condition card totals 2 registered trials; most-linked intervention Inactivated Trivalent Influenza vaccine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.